168 employees will be pink-slipped this quarter.
It was a particularly grim Monday for 200 Astellas employees in the US, who were informed that they were being let go and it was their last day with the company.
AstraZeneca is cutting 650 jobs in the US, "primarily in R&D," and consolidating its R&D operations at three "strategic R&D centers" in "bioscience clusters," academic and industrial beehives where the company can tap into concentrations of talent and infrastructure.
Pfizer and at least two other pharmas are spreading pink slips instead of cheer
WebMD is laying off 14% of its workforce in hopes of saving $45 million to offset revenue losses from an ongoing advertising slump that's plagued the portal throughout 2012.
AstraZeneca buys license to kidney drug; Targacept has another round of layoffs.
Merck slims down, Novo goes wide
The company said in a statement that proposed layoffs will help the drugmaker weather uncertainty on pricing and reimbursement in Europe.
Pharmas shrank their US sales forces by 7% between 2010 and 2011, but the pain wasn't shared evenly between the biggest of pharmas, as a number of players scaled up.
When Pfizer's US Enbrel sales force gives way to Amgen's in July, reps risk layoff if they don't get picked up by Amgen or re-assigned to Pfizer's new JAK inhibitor.
Takeda said it will slash its global workforce by around 2,800 jobs - 700 of those in the US and the rest in Europe - as it absorbs Nycomed and moves toward a more diverse product portfolio.
Novartis will eliminate 1,630 sales rep jobs and 330 headquarters marketing jobs as its hypertension franchise faces the impending loss of Diovan patent exclusivity and the impact of ugly study results on Tekturna sales.
AstraZeneca is slashing its US sales force by 24% as the company confronts a steep patent cliff and late-stage pipeline that has delivered a string of disappointments in recent years.
Sanofi will winnow its field force down through a "voluntary separation program" and relocation of some reps, said a spokesperson following news of another round of layoffs at the company.
Dendreon is downsizing to the tune of around 500 jobs and COO Hans Bishop is on the outs as the company struggles to launch its prostate cancer vaccine Provenge, which is seeing glacial uptake amid reimbursement woes.
San Francisco-based biotech Medivation said it will cut 23 positions -- a fifth of its staff -- as part of a cost-cutting exercise in the wake of the failure of Alzheimer's drug candidate dimebon, which the firm was partnering with Pfizer on.
UCB is getting out of the US primary care market by the end of the month to focus on its specialty immunology and neurology franchises.
Novartis' US sales reorg seems to have paid off in 2009 as the company held the line on sales and marketing expenses despite a passel of global launches.
Pfizer will shrink the square footage of its global R&D operation by 35% as it absorbs Wyeth, sharply reducing some sites, shuttering others and prompting an as-yet unspecified number of layoffs.
Johnson & Johnson will slash headcount by 6-7% -- between 7,020 and 8,190 of its 117,000 employees worldwide -- as part of a broad restructuring.
Amicus Therapeutics announced a work-force reduction of about 20 percent, or 26 employees, as a part of a corporate restructuring after a commercialization deal with Shire soured.
Eli Lilly & Co. will eliminate around 300 positions in its US diabetes, neuroscience and osteoporosis sales forces as it implements a new sales model featuring smaller territories, each manned by a rep with deep therapeutic expertise.
Amylin is cutting 200 sales positions -- around 35% of its sales force -- as it merges its specialty and primary care sales forces into a single organization targeting endocrinologists and diabetes-focused primary care physicians.
Johnson & Johnson will cut 900 positions at its Ortho-McNeil-Janssen Pharmaceuticals unit by the end of the second quarter.
Job security for pharma sales reps is looking bleak, going by the results of a ZS Associates study. The survey found that the number of US reps has plummeted 10% since 2007 to 92,000, and the management consultancy projects a further decline, to 75,000 by 2012.
KV Pharmaceutical Company said it is eliminating 700 jobs as part of a cost-cutting program following a suspension of manufacturing and product recalls resulting from an FDA investigation.
Allergan announced it will lay off 460 employees, mainly in sales and marketing, while King Pharmaceuticals said it would cut 760 positions, including 380 field sales staff.
The cuts keep coming. AstraZeneca will make another 6,000 job cuts for a total of 15,000, or 23% of its global workforce of 65,000, by 2013, and Sepracor is slashing its sales force.
Pfizer will cut between 18,000 and 19,000 jobs as it absorbs Wyeth, the company said.
AstraZeneca (AZ) announced plans to cut an additional 1,400 jobs - on top of the previously announced 7,600 - as the company deals with impending generic competition.
Specialty medicines continue to be a hot category, one in which spending has surged behind products that treat medicine's most complex diseases. This eBook lays out the needs and hurdles along the specialty drug pathway, explaining how stakeholders are working to get meds into patients' hands and ease their experience. Click here to download.